Irina Stepanov1, Prakash C Gupta2, Gauri Dhumal2, Katrina Yershova3, William Toscano4, Dorothy Hatsukami3, Mark Parascandola5. 1. Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA Division of Environmental Health Sciences, University of Minnesota, Minneapolis, Minnesota, USA. 2. Healis-Sekhsaria Institute for Public Health, Mumbai, Maharashtra, India. 3. Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA. 4. Division of Environmental Health Sciences, University of Minnesota, Minneapolis, Minnesota, USA. 5. Tobacco Control Research Branch, National Cancer Institute, Bethesda, Maryland, USA.
Abstract
INTRODUCTION: Recently, a tobacco product, Chaini Khaini, identified as snus appeared in India. The product marketing emphasises its discreet nature and explicitly claims safety by referring to the existing evidence on Swedish snus. We analysed tobacco-specific nitrosamines and nicotine in 12 samples of Chaini Khaini purchased in 2013 at open markets in India. METHODS: Samples were purchased twice: in March 2013 from Mumbai and in November 2013 from Mumbai and Ahmedabad. Chemical constituents were measured by our routine validated methods. RESULTS: Levels of carcinogenic nitrosamines NNN, NNK and NNAL averaged 22.9 (±4.9), 2.6 (±1.0) and 3.1 (±1.5) µg/g tobacco (wet weight), respectively. The levels of NAB, which is normally present in trace levels in tobacco products, ranged from 3.9 to 12.9 µg/g tobacco. Total nicotine levels in all samples averaged 10.0 mg/g tobacco and unprotonated nicotine accounted for an average 95.4% of the total nicotine content. CONCLUSIONS: Chaini Khaini, which is labelled as snus and is marketed as a safe alternative to other tobacco products contains very high levels of carcinogenic nitrosamines and biologically available nicotine. Interventions are urgently needed to educate current and potential consumers of this product. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
INTRODUCTION: Recently, a tobacco product, Chaini Khaini, identified as snus appeared in India. The product marketing emphasises its discreet nature and explicitly claims safety by referring to the existing evidence on Swedish snus. We analysed tobacco-specific nitrosamines and nicotine in 12 samples of Chaini Khaini purchased in 2013 at open markets in India. METHODS: Samples were purchased twice: in March 2013 from Mumbai and in November 2013 from Mumbai and Ahmedabad. Chemical constituents were measured by our routine validated methods. RESULTS: Levels of carcinogenic nitrosamines NNN, NNK and NNAL averaged 22.9 (±4.9), 2.6 (±1.0) and 3.1 (±1.5) µg/g tobacco (wet weight), respectively. The levels of NAB, which is normally present in trace levels in tobacco products, ranged from 3.9 to 12.9 µg/g tobacco. Total nicotine levels in all samples averaged 10.0 mg/g tobacco and unprotonated nicotine accounted for an average 95.4% of the total nicotine content. CONCLUSIONS: Chaini Khaini, which is labelled as snus and is marketed as a safe alternative to other tobacco products contains very high levels of carcinogenicnitrosamines and biologically available nicotine. Interventions are urgently needed to educate current and potential consumers of this product. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Entities:
Keywords:
Carcinogens; Harm Reduction; Nicotine; Packaging and Labelling
Authors: David T Levy; Elizabeth A Mumford; K Michael Cummings; Elizabeth A Gilpin; Gary Giovino; Andrew Hyland; David Sweanor; Kenneth E Warner Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-12 Impact factor: 4.254
Authors: Stephen B Stanfill; Gregory N Connolly; Liqin Zhang; Lily T Jia; Jack E Henningfield; Patricia Richter; Tameka S Lawler; Olalekan A Ayo-Yusuf; David L Ashley; Clifford H Watson Journal: Tob Control Date: 2010-11-25 Impact factor: 7.552
Authors: P C Gupta; C S Ray; S S Narake; K M Palipudi; D N Sinha; S Asma; G Blutcher-Nelson Journal: Indian J Cancer Date: 2012 Oct-Dec Impact factor: 1.224
Authors: Jiachen Zhou; Dominique S Michaud; Scott M Langevin; Michael D McClean; Melissa Eliot; Karl T Kelsey Journal: Int J Cancer Date: 2012-10-11 Impact factor: 7.396
Authors: Jeffrey S Stein; A George Wilson; Mikhail N Koffarnus; Michael C Judd; Warren K Bickel Journal: Psychopharmacology (Berl) Date: 2016-10-11 Impact factor: 4.530
Authors: A G Unnikrishnan; R K Sahay; Uday Phadke; S K Sharma; Parag Shah; Rishi Shukla; Vijay Viswanathan; S K Wangnoo; Santosh Singhal; Mathew John; Ajay Kumar; Mala Dharmalingam; Subodh Jain; Shehla Shaikh; Willem J Verberk Journal: PLoS One Date: 2022-03-31 Impact factor: 3.240
Authors: Shannon Gravely; Geoffrey T Fong; Pete Driezen; Steve Xu; Anne C K Quah; Genevieve Sansone; Prakash C Gupta; Mangesh S Pednekar Journal: BMC Public Health Date: 2016-12-13 Impact factor: 3.295